当前位置:首页 - 行情中心 - 艾德生物(300685) - 财务分析 - 现金流量表

艾德生物

(300685)

  

流通市值:69.23亿  总市值:69.32亿
流通股本:3.90亿   总股本:3.90亿

现金流量表

报告期2026-06-302026-03-312025-12-312025-09-30
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金629,965,574.62334,173,795.281,200,445,619.03870,428,221.69
  收到其他与经营活动有关的现金25,181,352.227,100,761.8352,201,882.3945,712,713.61
  经营活动现金流入小计655,146,926.84341,274,557.111,252,647,501.42916,140,935.3
  购买商品、接受劳务支付的现金75,056,551.4836,768,495.09145,339,557.51108,066,812.41
  支付给职工以及为职工支付的现金187,791,238.1111,671,639.69334,700,879.36255,460,199.33
  支付的各项税费84,406,305.4733,943,038.46150,955,541.85116,092,977.15
  支付其他与经营活动有关的现金113,187,206.1351,603,426.64256,827,463.19161,134,352.94
  经营活动现金流出小计460,441,301.18233,986,599.88887,823,441.91640,754,341.83
  经营活动产生的现金流量净额194,705,625.66107,287,957.23364,824,059.51275,386,593.47
二、投资活动产生的现金流量:
  收回投资收到的现金402,152,944.33152,790,000275,435,885.97259,409,989.45
  取得投资收益收到的现金3,582,161.93315,337.516,548,988.939,461,421.06
  处置固定资产、无形资产和其他长期资产收回的现金净额--1,843,271.24-
  投资活动现金流入小计405,735,106.26153,105,337.5293,828,146.14268,871,410.51
  购建固定资产、无形资产和其他长期资产支付的现金20,637,974.9913,154,595.4570,225,194.7955,714,823.78
  投资支付的现金338,146,662.61318,640,387.8455,500,636.38337,837,164.51
  投资活动现金流出小计358,784,637.6331,794,983.25525,725,831.17393,551,988.29
  投资活动产生的现金流量净额46,950,468.66-178,689,645.75-231,897,685.03-124,680,577.78
三、筹资活动产生的现金流量:
  取得借款收到的现金94,000,00094,000,000100,995,284.1890,000,000
  收到其他与筹资活动有关的现金--682,950.42153,559.36
  筹资活动现金流入小计94,000,00094,000,000101,678,234.690,153,559.36
  偿还债务支付的现金2,540,000950,00045,749,333.3345,100,000
  分配股利、利润或偿付利息支付的现金177,730,086.34666,215.99118,947,538.97117,368,747.71
  支付其他与筹资活动有关的现金171,431,817.9484,219,682.1438,684,408.5636,689,965.99
  筹资活动现金流出小计351,701,904.2885,835,898.13203,381,280.86199,158,713.7
  筹资活动产生的现金流量净额-257,701,904.288,164,101.87-101,703,046.26-109,005,154.34
四、汇率变动对现金及现金等价物的影响-32,426,556.57-12,942,140.83-5,142,146.983,602,104.04
五、现金及现金等价物净增加额-48,472,366.53-76,179,727.4826,081,181.2445,302,965.39
  加:期初现金及现金等价物余额341,543,017.06341,543,017.06315,461,835.82315,461,835.82
  期末现金及现金等价物余额293,070,650.53265,363,289.58341,543,017.06360,764,801.21
补充资料:
  净利润166,125,204.53-361,255,321.05-
  资产减值准备4,128,369.07-31,105,393.02-
  固定资产和投资性房地产折旧21,270,116.27-42,306,936.09-
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧21,270,116.27-42,306,936.09-
  无形资产摊销3,426,082.54-8,266,177.06-
  长期待摊费用摊销847,624.35-3,554,317.46-
  处置固定资产、无形资产和其他长期资产的损失-9,711.62--487,729.6-
  固定资产报废损失692,543.87-2,842,913.33-
  公允价值变动损失-2,520,871.82--5,727,685.2-
  财务费用2,120,933.96-8,891,184.37-
  投资损失-685,258.34--8,901,527.36-
  递延所得税-334,847.02--2,419,301.65-
  其中:递延所得税资产减少-571,149.8--2,508,424.37-
    递延所得税负债增加236,302.78-89,122.72-
  存货的减少-8,891,958.22--2,972,577.19-
  经营性应收项目的减少14,310,375.89--105,044,560.22-
  经营性应付项目的增加-7,997,859.75-27,690,826.02-
  现金的期末余额293,070,650.53-341,543,017.06-
  减:现金的期初余额341,543,017.06-315,461,835.82-
  现金及现金等价物的净增加额-48,472,366.53-26,081,181.24-
公告日期2026-08-252026-04-282026-04-162025-10-25
审计意见(境内)标准无保留意见
TOP↑